T cell protein tyrosine phosphatase (TCPTP) dephosphorylates a number of substrates, including JAK-STAT (signal transducer and activator of transcription) signaling proteins, which are activated by interferon (IFN)-␥, a major proinflammatory cytokine involved in conditions such as inflammatory bowel disease. A critical function of the intestinal epithelium is formation of a selective barrier to luminal contents. The structural units of the epithelium that regulate barrier function are the tight junctions (TJs), and the protein composition of the TJ determines the tightness of the barrier. Claudin-2 is a TJ protein that increases permeability to cations and reduces transepithelial electrical resistance (TER). We previously showed that transient knockdown (KD) of TCPTP permits increased expression of claudin-2 by IFN-␥. Here, we demonstrate that the decreased TER in TCPTP-deficient epithelial cells is alleviated by STAT1 KD. Moreover, increased claudin-2 in TCPTP-deficient cells requires enhanced STAT1 activation and STAT1 binding to the CLDN2 promoter. We also show that mutation of this STAT-binding site prevents elevated CLDN2 promoter activity in TCPTP-deficient epithelial cells. In summary, we demonstrate that TCPTP protects the intestinal epithelial barrier by restricting STAT-induced claudin-2 expression. This is a potential mechanism by which loss-of-function mutations in the gene encoding TCPTP may contribute to barrier defects in chronic intestinal inflammatory disease.
Introduction
The inflammatory bowel disease (IBD) candidate gene protein tyrosine phosphatase nonreceptor type 2 (PTPN2) encodes the ubiquitously expressed T cell protein tyrosine phosphatase (TCPTP) protein. 1 TCPTP directly dephosphorylates a number of substrates involved in cytokine and growth factor signaling, including members of the signal transducer and activator of transcription (STAT) family of transcription factors. [2] [3] [4] We and others have shown that TCPTP acts as a negative regulator of interferon-␥ (IFN-␥ ) signaling, as knockdown (KD) of TCPTP permits increased activation of STAT1 and STAT3 in intestinal epithelial cells (IECs). [5] [6] [7] Since TCPTP dephosphorylates STAT proteins in the cytoplasm and upon their translocation to the nucleus, it therefore plays an important role in limiting the downstream signaling initiated by inflammatory cytokines, such as IFN-␥ . [7] [8] [9] Lossof-function mutations in the PTPN2 locus are associated with IBD, celiac disease, and type 1 diabetes, conditions that are also associated with increased intestinal permeability early in disease. [10] [11] [12] [13] [14] [15] [16] [17] We have previously shown that transient loss of TCPTP expression by small interfering RNAs (siRNAs) in IECs predispose to a more severe barrier defect induced by the IBD cytokine IFN-␥ . 18, 19 Specifically, we observed reduced transepithelial electrical resistance (TER) and increased permeability to FITC-dextran but no evidence of apoptosis. This is in agreement with other studies indicating that induction of epithelial apoptosis by IFN-␥ is not a major contributor to barrier dysfunction. 20, 21 The barrier defects observed in our previous studies doi: 10 .1111/nyas.13439 of IFN-␥ treatment of transient TCPTP siRNA KD IECs were associated with altered membrane localization of the tight junction (TJ) regulatory protein zonula occludens-1 (ZO-1) and increased expression of the cation-pore forming TJ protein claudin-2. 18, 19 Claudin-2 is a molecule of clinical significance, as its expression is increased in IBD, and it is also associated with metastatic potential in colorectal cancer. [22] [23] [24] [25] [26] [27] Increased claudin-2 in epithelial TJs makes them more permissive to passive paracellular flux of sodium ions. [28] [29] [30] In addition, claudin-2 has been described as having the properties of a water channel. 31, 32 Thus, given its capacity to act as a high-conductance cationpermeable paracellular pore, we can appreciate how elevated claudin-2 could increase cation flux into the intestinal lumen and thus contribute to fluid loss consistent with diarrhea. 33 We previously described a STAT-binding site in the CLDN2 promoter. 18 The aim of this study was to determine whether stable KD of TCPTP in IECs leads to increased expression of claudin-2 through STAT-mediated transcriptional regulation. Our results demonstrate that loss of TCPTP expression in IECs promotes increased expression and membrane localization of claudin-2 following IFN-␥ treatment, which occurs in a STAT1-dependent manner. We further show that STAT1 binds to the CLDN2 promoter and that mutation of the STAT-binding site eliminates IFN-␥ induction of claudin-2. These data have implications for our understanding of how TCPTP restricts IFN-␥ signaling and how disease-associated loss-of-function mutations in PTPN2 may exacerbate barrier defects in chronic inflammatory diseases of the intestines.
Methods

Materials
Human recombinant IFN-␥ (Roche, Mannheim, Germany), monoclonal mouse anti-␤-actin (Sigma-Aldrich, St. Louis, MO), monoclonal mouse anti-TCPTP antibody CF-4, which detects the 45-and 48-kDa isoforms (Millipore, Billerica, MA), anti-phospho-STAT1 (Tyr 701 ), anti-STAT1 (Cell Signaling Technologies, Danvers, MA), anti-claudin-2, anti-occludin, anti-CDX2, and anti-ZO-1 antibodies (Invitrogen, Waltham, MA) were obtained from the sources noted. Millicell culture plate inserts were purchased from Millipore Corporation (Bedford, MA). McCoy's 5A and DMEM media were purchased from Corning Inc. (Corning, NY). The ON-TARGET plus SMART pool siRNA and ON-TARGET plus Nontargeting pool were purchased from GE Dharmacon (Pittsburgh, PA). All other reagents were of analytical grade and acquired commercially.
Tissue culture
Human Caco-2bbe and HT-29 IECs were grown in Dulbecco's modified Eagle's medium and McCoy's 5A medium, respectively (HyClone Laboratories Inc., Logan, UT) with 10% heat-inactivated fetal bovine serum and 1% glutamine and penicillin (100 U/mL)/streptomycin (100 g/mL) at 37°C in 5% CO 2 . Cells were fed three times a week.
Stable shRNA PTPN2-deficient cell line generation As previously described, control shRNA and shRNA against PTPN2 (Sigma-Aldrich) were transfected into HEK293T cells along with packaging vector (pR8.2) and ENV plasmid (pMDG.2) (gifts from Dr. R. Daniel Beauchamp, Vanderbilt University, Nashville, TN) using Effectene reagent (Qiagen, Valencia, CA). 34 After 18 h, the cells were washed, and fresh media was added to the cells for 48 h, after which the cell supernatant was collected and filtered through a 0.45-M filter (Millipore, Billerica, MA). The filtered media was used to infect HT-29 and Caco-2bbe cells by mixing equal amounts of fresh media with polybrene (5 mg/mL). After 72-96 h of infection, cells were stably selected using puromycin (1 g/mL). The stable cell lines were maintained with 500 ng/mL puromycin. PTPN2 KD was confirmed by both real-time PCR (RT-PCR) and immunoblotting methods.
Small interfering RNA transfection HT-29 control shRNA (Con-shRNA) and PTPN2-KD IECs were seeded (5 × 10 5 cells on six-well plates and 2 × 10 5 cells on glass coverslips) and grown overnight. The next day, STAT1 siRNA SMARTpool and Control siRNA SMARTpool (25 nM final concentration) were transfected into HT-29 Con-shRNA and PTPN2-KD cells using the DharmaFECT reagent according to the manufacturer's instructions. After 24 h of transfection, the cells were treated with IFN-␥ for another 24 hours. The cells were either lysed with RIPA for western blot analysis or fixed with either 4% PFA or 100% methanol for immunofluorescence studies. 
RNA isolation, real-time PCR, and quantitative PCR
The control and PTPN2-KD cell lines were plated on six-well plates, and total RNA was extracted using TRIzol reagent according to the manufacturer's instructions. RNA purity and concentration were assessed by absorbance at 260 and 280 nm. One microgram of total RNA was taken, and cDNA was made using qScript cDNA SuperMix (Quanta Biosciences, Beverly, MA). Two microliters of 5× -diluted cDNA was amplified using gene-specific primers and GoTaq Green, 2× mix (Promega Madison, WI; sequences listed in Table 1 ). For quantitative PCR (qPCR), the cDNA was prepared as described earlier. The qPCR was performed using a PowerUp SYBR Green Master Mix (Applied Biosystems, Foster City, CA) and a CFX96 Touch TM RealTime PCR Detection System (Bio-Rad, Hercules, CA), with gene-specific primers under the following conditions: 95°C for 3 min, followed by 40 cycles at 95°C for 15 s, 55°C for 30 s, and 72°C for 30 seconds. Measurements were performed in triplicate; human GAPDH was used as an endogenous control. The qPCR data were analyzed by the comparative C T ( CT) method, as previously described. 35 
Preparation of Triton X-100-soluble and -insoluble fractions
The control and PTPN2-KD cell lines were seeded (1 × 10 6 ) on a 10-cm dish and grown for 3 days, and preparation of Triton X-100-soluble and -insoluble fractions was performed as described in published protocols. 36 In brief, cells were washed with 1× phosphate-buffered saline (PBS) and scraped in cold PBS. The cells were spun down at 400 × g for 5 min, and the pellet was lysed with lysis buffer (10 mM HEPES, pH 7.2, 1% Triton X-100, 100 mM NaCl, 2 mM EDTA, with phosphatase and protease inhibitors) and incubated at 4°C for 20 min, followed by centrifugation at 9600 × g for 20 minutes. The resulting supernatant was considered the soluble fraction. The pellet from the soluble fraction was dissolved by pipetting in pellet solubilization buffer (10 mM HEPES, pH 7.2, 1% SDS, 100 mM NaCl, 2 mM EDTA, with phosphatase and protease inhibitors), and the samples were sonicated (10-s off and 10-s on cycle) for 2 min and incubated at 4°C for 20 min, followed by centrifugation at 16,200 × g for 20 minutes. The supernatant was considered the insoluble fraction. Protein concentration was determined by the bicinchoninic acid (BCA) method using the respective lysis buffer as a blank.
Western blotting (SDS-PAGE)
The control and KD cells were seeded on sixwell plates. After experimental treatments, the cells were washed with PBS and lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, with protease and phosphatase inhibitors) for 10 min at 4°C. The lysate was sonicated (10-s off and 10-s on cycle) for 2 min and centrifuged at 16,200 × g for 10 minutes. The supernatant was transferred to a new tube, and protein concentration was determined by the BCA method using the Pierce BCA protein assay reagent (Pierce, Rockford, IL). A 20-g total protein amount was suspended in 1% SDS sample buffer, heated for 10 min at 95°C, resolved on a 6-12% SDS-PAGE gel, and transferred to a PVDF membrane (Millipore). The blots were blocked in 5% TBS-T (5% dry milk powder in Trisbuffered saline, 0.01% Tween-20) for 30 min, followed by incubation with primary antibody diluted in 1% TBS-T overnight at 4°C. The blots were then washed five times for 5 min at room temperature with TBS-T (0.1% Tween-20), incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature, and washed five times for 5 min at room temperature with TBS-T (0.1% Tween-20). Specific labeling was detected by chemiluminescence reagent (Pierce) and exposure to X-ray film (Labscientific Inc., Livingston, NJ). Densitometric analysis of western blots was performed using Image J software (NIH).
Small interfering RNA transfection of polarized IEC monolayers
The HT-29 Con-shRNA and PTPN2-KD IECs were seeded (5 × 10 5 cells on 12-well Transwells in triplicate) and grown for 7 days. On day 8, the TER across control and KD cell monolayers was assessed using a voltohmmeter (WPI, Sarasota, FL) and companion electrodes (Millipore). This time point was considered the 0 h time point. The media was changed, and cells were transfected either with STAT1 siRNA SMARTpool or with control siRNA SMARTpool (25 nM final concentration) into HT-29 Con-shRNA and PTPN2-KD cells using the DharmaFECT reagent according to the manufacturer's instructions (sequences listed in Table 2 ). After 24 and 48 h of transfection, the TER was measured in triplicate in each insert, and the mean was calculated to represent that individual time point in that individual insert. Measurements were calculated in ·cm 2 and expressed as percent change in TER over time.
Immunoprecipitation
The cells were washed twice with 1 × PBS and lysed with lysis buffer (30 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM Mg acetate, and 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)). After 30 min of incubation rotating end over end at 4°C, the lysates were centrifuged at 16,200 × g for 15 min at 4°C to remove the cell debris. Samples were precleared using 100 g of lysate protein with 50 L of Dynabeads for 2 h at 4°C. For immunoprecipitation, the anti-TCPTP antibody or nonspecific immunoglobulin G (IgG) was incubated with Dynabeads for 1 h at room temperature. The beads were washed twice with PBS, resuspended in 200 mM triethanolamine (pH 8.2), and incubated for 10 min at room temperature. The beads were cross-linked with 20 mM dimethyl pimelimidate dihydrochloride for 30 min at room temperature. The Dynabeads were washed with 50 mM Tris-HCl (pH 7.5) for 15 min and then three times with TBS. The washed Dynabeads were incubated with precleared lysates overnight. Beads were washed with lysis buffer three times, eluted with 1.5% SDS-PAGE sample buffer, and incubated for 10 min at 70°C. The supernatant was analyzed by SDS-PAGE as described earlier.
Chromatin immunoprecipitation assay
After 2 days of seeding, Con-shRNA and PTPN2-KD cells were treated with IFN-␥ (1000 U/mL (100 ng/mL)) for 24 hours. Cells were then cross-linked with formaldehyde (1% final concentration) and incubated for 10 min at room temperature. The cells were quenched by addition of glycine to each plate to reach a final concentration of 125 mM and incubated for 5 minutes. The media was removed, and the cells were washed (×2) with 10 mL of ice cold 1× PBS. The cells were incubated with 4 mL of ice cold 1× PBS with appropriate protease inhibitors, and cells were scraped and transferred to a 15-mL conical tube and spun at 750 × g for 10 min at 4°C. The cell pellet was resuspended in 1 mL of nuclear lysis buffer (50 mM Tris-HCl (pH8), 10 mM EDTA, and 1% SDS). The samples were sonicated (10-s off, 10-s on cycle) for 2 min and centrifuged at 16,200 × g for 15 minutes. The DNA concentration was measured, and 100 g of precleared chromatin was incubated with anti-STAT1 antibody or with rabbit IgG at 4°C overnight. The magnetic beads were pelleted using the Magnetic Particle Concentrator and washed in high-salt buffer (×4). The beads were washed twice with TB buffer and resuspended in 300 L of elution buffer (50 mm Tris-Cl, 10 mM EDTA) with proteinase K (20 g/L) and then incubated for 2 h at 55°C. The samples were cross-linked overnight at 65°C. The samples were then centrifuged at 16,200 × g for 5 min and resuspended in 50 L of TE buffer. The 5 L of purified DNA was taken, and PCR was performed using CLDN2 promoter-specific primers.
CLDN2 promoter luciferase reporter assay
The human CLDN2 promoter (from -900 bp to +112 bp) gene construct was purchased from Integrated DNA Technologies (IDT; Coralville, IA). The construct was cloned into the luciferase vector pGL3-Basic (Promega; restriction enzyme sites NheI and KpnI, respectively), and the sequence of the product was confirmed by sequencing analyses. A single mutation of the STAT binding site was generated using forward primer 5 -CATCATCACCT TCCGGGAAAGCAGCCA-3 and reverse primer 5 -GTGGCTGCTTTCCCGGAAGGTGATGATG-3 . A triple mutation was generated using forward primer 5 -CCACTGCCATCACCTTTCCCGAGAGCAGC CACC-3 and reverse primer 5 -GGTGGCTGCTC TCGGGAAAGGTGATGATGGCAGTGG-3 . The mutations were confirmed by sequencing analysis. The cells were seeded onto 12-well plates in triplicate (technical replicates) and allowed to grow overnight to reach 50-60% confluence. The following day, cells were cotransfected with a firefly luciferase reporter construct and a reference construct that contains Renilla reniformis luciferase, phRL-TK (Promega), using Effectene reagent (Qiagen). After 24-h transfection, the cells were treated with IFN-␥ (1000 U/mL (100 ng/mL)). Twenty-four hours later, luciferase activities were measured using the Dual Luciferase Reporter Assay System kit (Promega) in a Glomax multidetection system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity and plotted as mean ± SEM from three independent experiments.
Immunofluorescence staining and quantification HT-29 control and PTPN2-KD cell lines were plated on coverslips (12-well) and cultured for 3 days. After treatment, the cells were washed (×2) with PBS and fixed with either 100% methanol for 5 min at -20°C or with 4% PFA for 20 min at room temperature. Cells were washed (×2) with PBS and permeabilized with 0.3% Triton X-100 in PBS for 30 min at room temperature. Cells were washed (×2) with PBS and blocked with 10% normal donkey serum (Jackson ImmunoResearch) for 30 min at room temperature. Cells were incubated overnight at 4°C with primary antibodies diluted in 1% normal donkey serum and 0.01% Tween-20 in PBS. The next day, cells were washed five times for 5 min at room temperature with 0.01% Tween-20 in PBS (PBS-T). The cells were incubated with appropriate secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594 for 1 h at room temperature. At the end of the incubation, cells were washed (×5) with PBS-T and then washed in water and mounted with ProLong Gold plus DAPI (Invitrogen). All images were captured with a Leica DM5500 microscope attached to a DFC365 FX camera using a 63× oil immersion objective with an additional 2× digital zoom. The individual images were converted to tiff files with the LAS-AF lite software, and Photoshop (Adobe) was used to create the final figures. The total fluorescence measurements were performed with Image J software, and densitometric analysis was performed on 9-10 images from three different fields of view.
Statistical analysis
All data are mean ± SEM for a series of experiments. Technical replicates are indicated in the specific description of the relevant method. The 
Results
Stable KD of TCPTP causes increased claudin-2 expression in intestinal epithelial cell lines
We utilized two stable PTPN2-KD IEC lines generated using parental Caco-2bbe and HT-29 cells. Transfection of PTPN2 shRNA reduced PTPN2 mRNA compared with cells transfected with control shRNA or parental Caco-2bbe and HT-29 cells as determined by qPCR, thus confirming our previous data in HT-29 PTPN2-KD IECs (Fig. 1A and B) . 34 KD of PTPN2 mRNA was specific, as mRNA of the closely related protein tyrosine phosphatase PTP1B was unaffected compared with control shRNA and parental HT-29 IECs (Fig. 1C) . The mRNA levels of the PTPs SHP1 and SHP2 were also unaffected by PTPN2 shRNA (Fig. 1D and 1E) . We previously demonstrated a reduction in TCPTP protein levels in PTPN2-KD IECs by probing whole-cell lysates. Here, we confirmed TCPTP KD by specifically immunoprecipitating TCPTP from cell lysates of Con-shRNA and PTPN2-KD HT-29 IECs and probing for TCPTP levels by cross-linking (E) Phosphorylated STAT1 levels relative to total STAT1 were quantified by densitometry and normalized to ␤-actin (n = 5). (F) Claudin-2 protein levels were quantified by densitometry and normalized to ␤-actin (n = 5). Statistical significance was calculated using one-way analysis of variance followed by Student-Newman-Keuls posttest. *P < 0.05, **P < 0.01, ***P < 0.001 versus Con-shRNA in panel B; versus C-Csi-U in panels E and F. ## P < 0.01, ### P < 0.001 versus KD-Csi-U. (Fig. 1F) . Quantification of the resulting western blots confirmed significant KD of TCPTP protein equivalent to the reduction in mRNA levels (Fig. 1G) . We previously reported that PTPN2-KD IECs exhibit reduced TER, even in the absence of inflammatory cytokine challenge. 34 The transmembrane protein claudin-2 forms a cation-selective pore in the apical TJ that increases permeability to cations, such as sodium, and reduces TER. 29, 30, 33 To determine whether the previously described decrease in TER in PTPN2-KD IECs is associated with reduced transcription of claudin-2, we probed for CLDN2 mRNA levels by RT-PCR and qPCR. PTPN2-KD cells showed significantly increased CLDN2 mRNA compared with control and parental cells in both Caco-2bbe ( Fig. 1H and 1I ) and HT-29 cell lines (Fig. 1J) .
Increased STAT1 phosphorylation in PTPN2-KD IECs mediates IFN-␥ -stimulated claudin-2 protein expression
Confirmation that claudin-2 protein expression was increased in PTPN2-KD cells (HT-29) was provided by western blotting, which showed reduced TCPTP correlated with significantly increased claudin-2 levels in both the cytosol (Triton-X-soluble) and, as expected, in the cell membrane (Triton-Xinsoluble) fractions of cell lysates ( Fig. 2A and  2B ). In support of these data and in agreement with earlier findings, immunofluorescence staining identified increased claudin-2 levels in cell-cell junctions in PTPN2-KD HT-29 IECs (Fig. 2C) . 29, 30, 34 STAT1 is a key mediator of cytokine signaling pathways and is a prominent substrate of TCPTP. Dephosphorylation of STAT1 on its key activating tyrosine residue (Y701) reduces its transcriptional activity. TCPTP can dephosphorylate STAT1 in the cytoplasm and the nucleus and thus plays an essential role in restricting STAT1-mediated signaling and transcription. 5, 7 We previously observed that transient KD of TCPTP by siRNA permits increased STAT1 phosphorylation by IFN-␥ and that the CLDN2 promoter contains a STAT-binding site. 18 Here, we investigated whether this was recapitulated in stable PTPN2-KD IECs and whether the elevation in STAT1 was responsible for the increase in claudin-2 in these cells. Control shRNA and PTPN2-KD HT-29 IECs were transfected with control (scrambled) siRNA or STAT1 siRNA. STAT1 (Y701) phosphorylation, STAT1 expression, and claudin-2 expression were determined in these transfected cells with or without IFN-␥ treatment for 24 h (1000 U/mL (100 ng/mL)).
18,19,37 STAT1 phosphorylation was increased in untreated and IFN-␥ -treated PTPN2-KD cells compared with respective untreated control shRNA IECs (Fig. 2D , lanes 1 and 2 versus 4 and 5, respectively). Claudin-2 expression was also confirmed to be higher in PTPN2-KD IECs with or without IFN-␥ treatment. KD of STAT1 by siRNA reduced STAT1 phosphorylation and total STAT1 in untreated control shRNA (Fig. 2D, lane 3 ; Fig. 2E ) and PTPN2-KD IECs (Fig. 2D, lane 7 ; Fig. 2E ), as well as IFN-␥ -treated control shRNA (Fig. 2D, lane 4; Fig. 2E ) and PTPN2-KD (Fig. 2D,  lane 8; Fig. 2E ) IECs. STAT1 siRNA also reduced claudin-2 expression in untreated PTPN2-KD IECs (Fig. 2D, lane 5 versus lane 7; Fig. 2F ) and following IFN-␥ treatment (Fig. 2D , lane 6 versus lane 8; Fig. 2F ). These data demonstrate that STAT1 KD reversed the elevated claudin-2 expression observed in PTPN2-KD IECs at rest and following IFN-␥ treatment.
STAT1 siRNA reduced junctional membrane-localized claudin-2 and STAT1 nuclear translocation in PTPN2-KD IECs
To determine whether STAT1 regulates claudin-2 localization at cellular junctions, the required site for claudin-2 to functionally modify cation flux, we performed claudin-2 immunolocalization by confocal microscopy. HT-29 Con-shRNA and PTPN2-KD IECs cultured on glass coverslips were transfected with control or STAT1 siRNAs. After 24 h, IFN-␥ was added for a period of 24 hours. Cells were fixed with either 4% PFA or 100% methanol and stained for phosphorylated STAT1 (Y701) (p-STAT1) and claudin-2. To confirm decreased p-STAT1 and the effect of STAT1 siRNA in reducing claudin-2 levels in PTPN2-KD IECs (c.f. Fig. 2) , we first examined whether nuclear p-STAT1 was elevated in PTPN2-KD IECs and whether this could be reversed by STAT1 siRNA. Nuclear levels of phosphorylated STAT1 (Y701) were elevated in untreated PTPN2-KD IECs versus Con-shRNA IECs (Fig. 3A (i and v) ; Fig. 3B ) and substantially increased by IFN-␥ treatment (Fig. 3A (iii and  vii) ; Fig. 3B ). As expected, STAT1 siRNA reduced p-STAT1 levels in all conditions (Fig. 3A (ii, iv, vi, and viii); Fig. 3B ). The intensity of claudin-2 membrane localization was increased in untreated PTPN2-KD compared with untreated Con-shRNA IECs (Fig. 3C (i and v); Fig. 3D ). IFN-␥ treatment further increased membrane claudin-2 in control and PTPN2-KD IECs (Fig. 3C (iii and vii) ; Fig. 3D ). Claudin-2 staining was partly decreased by STAT1 siRNA transfection in untreated PTPN2-KD IECs, although this just failed to reach statistical significance (Fig. 3C (v and viii); Fig. 3D ). However, STAT1 KD in TCPTP-deficient cells significantly inhibited the IFN-␥ -induced increase in membrane claudin-2 compared with IFN-␥ -treated Con-shRNA IECs (Fig. 3C (iii and iv) ; Fig. 3D ) and PTPN2-KD IECs transfected with control siRNA (Fig. 3C (vii and viii); Fig. 3D ). Overall, these data confirmed that loss of TCPTP promotes claudin-2 expression and membrane localization through a mechanism involving, at least in part, increased phosphorylation and nuclear localization of STAT1.
KD of STAT1 rescued TER in PTPN2-KD IECs
To determine whether STAT1 siRNA altered the defective barrier function of PTPN2-KD IECs, STAT1 siRNA and control siRNA were transfected into control and PTPN2-KD HT-29 IEC monolayers cultured on Transwells to measure TER. PTPN2-KD IEC monolayers had a lower starting TER than Con-shRNA monolayers, consistent with our previously published data. 34 An siRNA KD of STAT1 in PTPN2-KD IECs significantly increased TER over 48 h compared with PTPN2-KD cells transfected with control siRNA ( Fig. 4A ; P < 0.01). By contrast, STAT1 KD in control cells did not significantly increase TER above the change observed in control siRNA-transfected Con-shRNA cells. To further confirm the effects of STAT1 KD, the percent change in TER due to KD of STAT1 in PTPN2-KD cells compared with STAT1 KD in Con-shRNA cells revealed that KD of STAT1 in PTPN2-KD cells induced a significant increase in TER over ConshRNA HT-29 cells (Fig. 4B ; 29.8 ± 3.9 versus 13.8 ± 4.2; P < 0.05). These data indicate that the underlying decrease in barrier function (TER) in PTPN2-KD IEC monolayers is mediated at least in part by STAT1 and, as indicated by the data presented in Figures 2 and 3 , likely occurs through elevated claudin-2 expression and localization to TJs.
IFN-␥ induces STAT1 binding to the CLDN2 promoter in PTPN2-KD IECs
We previously reported a STAT-binding site in the CLDN2 promoter (Fig. 5A) . 18 Several transcription factor-binding sites have been identified in the CLDN2 promoter, including for caudal-related homeobox 2 (CDX2), which can bind at the CDXB site. 38 Western blot analysis indicated no change in CDX2 expression in PTPN2-KD Caco-2bbe IECs compared with controls (Fig. 5B) . To determine whether STAT1 binds to the CLDN2 promoter region, we performed chromatin immunoprecipitation of STAT1 and probed for binding of the putative CLDN2 DNA-binding sequence. ConshRNA and PTPN2-KD IECs were treated with IFN-␥ for 24 h before STAT1 immunoprecipitation of cell lysates. RT-PCR analysis using primers against the STAT-binding region of the CLDN2 promoter ( Fig. 5C ; primers listed in Table 1 ) showed a significant (4.5 ± 1-fold; P < 0.05, n = 3) increase in binding of STAT1 to the CLDN2 promoter in PTPN2-KD IECs (Fig. 5D) . Confirmation of the specificity of recognition of the STAT-binding site by STAT1 antibody pulldown was made by the lack of detection of AP-1 and NF-B transcription factor-binding sites in the CLDN2 promoter as determined by RT-PCR (Fig. 5E ). These data indicate that, in TCPTP-deficient IECs, IFN-␥ is capable of inducing a significant level of STAT1 binding to the CLDN2 promoter consistent with the increase in STAT1 nuclear localization observed in Figure 3A (panel vii).
Mutation of the STAT-binding site reverses CLDN2 promoter induction in PTPN2-KD IECs
To confirm a functional role for TCPTP in restricting CLDN2 promoter activity, we generated a CLDN2 promoter-luciferase construct that we transfected into Con-shRNA or PTPN2-KD HT-29 cells. Resting luciferase activity was elevated in untreated PTPN2-KD IECs compared with Con-shRNA HT-29 cells (Fig. 5A) . Treatment with IFN-␥ (1000 U/mL (100 ng/mL); 24 h) significantly increased CLDN2-luciferase activity in PTPN2-KD IECs (Fig. 6A) . The cumulative effect of TCPTP KD and IFN-␥ treatment resulted in a 4.7 ± 0.8-fold increase in promoter activity compared with a 2.0 ± 0.5-fold increase following IFN-␥ treatment of Con-shRNA cells.
To determine whether the increased CLDN2 promoter activity in PTPN2-KD cells was due to increased STAT1 binding, we generated single (1M) and triple (3M) point mutations in the STATbinding site of the CLDN2 promoter ( Fig. 6B and  6C ). Both mutants abolished the elevated CLDN2-luciferase activity in PTPN2-KD IECs with or without IFN-␥ treatment (Fig. 6D ). These data demonstrate that the potentiation of CLDN2 promoter activity in PTPN2-KD IECs is mediated by STAT binding to the CLDN2 promoter.
Discussion
Both Crohn's disease (CD) and ulcerative colitis are characterized by their specific cytokine profile, with elevated levels of IFN-␥ predominating in CD. 39 Of the downstream pathways involved in transducing IFN-␥ receptor signals, STAT1 and STAT3, members of the STAT family of transcription factors, have perhaps received the most attention with respect to IFN-␥ -associated gene transcription. 40 Indeed, upregulation of both STAT1 and STAT3 has been observed in IBD, while both STAT1 and STAT3 have been identified as IBD risk candidate genes. [41] [42] [43] [44] We previously identified a STATbinding motif in the CLDN2 promoter 261-253 bp upstream of the transcription start site. 18 The identified sequence (5 -TTCCCGGAA-3 ) was a positive match for a possible STAT1-binding motif and a confirmed STAT3 binding motif in the human p21WAF gene. 45 We therefore set out to determine whether the increase in claudin-2 levels observed in PTPN2-KD IECs was mediated by STAT1 signaling and whether this putative STAT-binding motif was responsible for the elevated claudin-2 observed in TCPTP-deficient IECs treated with IFN-␥ . Using a novel PTPN2-KD IEC line, we demonstrated that siRNA KD of STAT1 partially reduced the elevated claudin-2 expression observed in both untreated and IFN-␥ -challenged PTPN2-KD IECs. In agreement with expression data, the elevated levels of claudin-2 in the epithelial membranes of PTPN2-KD IECs were also reduced by STAT1 siRNA. Furthermore, nuclear p-STAT1 was significantly elevated by IFN-␥ treatment of PTPN2-KD versus control cells and, as expected, reduced by STAT1 siRNA. These data support our hypothesis that TCPTP restricts claudin-2 expression, at least in part, through its negative regulation of STAT1 signaling. This was also supported by our data indicating that partial siRNA KD of STAT1 significantly increased TER in PTPN2-KD HT-29 monolayers. We further demonstrated a physical association between activated STAT1 and the CLDN2 promoter STAT-binding motif by ChIP analysis (c.f. Fig. 5 ). To understand the mechanism by which loss of TCPTP expression promoted increased claudin-2 transcription, we generated a CLDN2 promoter-luciferase construct to show that, under resting and IFN-␥ treatment conditions, CLDN2 promoter activity was increased compared with control-shRNA IECs expressing the same reporter construct. Mutations of the STATbinding motif completely negated the enhanced CLDN2 promoter activity in PTPN2-KD IECs.
Cumulatively, we have demonstrated that STAT1 binds to the CLDN2 promoter to increase CLDN2 expression via a STAT-binding motif. However, at this time we cannot rule out the involvement of other STATs in contributing to CLDN2 promoter activity in TCPTP-deficient IECs. Specifically, we can consider potential roles for STAT3 and STAT5 as TCPTP substrates and mediators of IFN-␥ signaling, as well as STAT6, which is an additional substrate of TCPTP and has previously been implicated in promoting claudin-2 levels in response to IL-13 stimulation and in an oxazolone colitis model. 25, [46] [47] [48] [49] Our data do not entirely align with previous studies that showed that pharmacological inhibition of IFN-␥ -stimulated STAT1 tyrosine phosphorylation was unable to alleviate IFN-␥ -induced reduction in TER. [50] [51] [52] In addition, the same group observed that STAT1 siRNA did not reverse IFN-␥ induction of a drop in TER; however, they did identify an essential role for STAT1 in promoting the capacity of STAT5b to mediate IFN-␥ -induced macromolecule (horseradish peroxidase) transepithelial flux across T84 colonic epithelial cells. This STAT5b-dependent mechanism involved formation of a complex involving Fyn Src kinase, the G protein adaptor molecule GAB2, and PI 3-kinase, thus indicating a requirement for STAT signaling in IFN-␥ -stimulated barrier permeability defects associated with macromolecule translocation. 47 Therefore, the potential roles of STAT proteins in the overall regulation of different aspects of epithelial permeability are clearly complex and likely have context-dependent, stimulus-dependent, and cell type-dependent influences. Our findings are also consistent with our earlier observations that, in the context of decreased TCPTP expression, the outcomes of IFN-␥ signaling are different than in TCPTP-competent cells. 53 This was perhaps best exemplified by the lack of a significant effect of IFN-␥ in stimulating claudin-2 expression in control IECs, which contrasted with the marked upregulation of claudin-2 by IFN-␥ in TCPTP-deficient IECs. 18, 37 Moreover, IFN-␥ -stimulated STAT1 activation was shown to only induce apoptosis of pancreatic ␤-islet cells when TCPTP levels were knocked down. 54 Thus, loss of TCPTP activity can change the profile of signaling outcomes governed by TCPTP substrates, such as members of the JAK-STAT pathway. Our data show that recruitment of STATmediated cytokine signaling is altered in TCPTPdeficient IECs and thus implicate TCPTP activity as a key checkpoint that can restrict the full complement of STAT-mediated transcriptional events.
The CLDN2 promoter contains a number of transcription factor-binding sites, including sites for NF-B, AP-1, HNF1A, GATA-4, and the intestinespecific transcription factor CDX2. 27, 33, 38, 55 CDX2 has been identified in a number of studies as a key transcription factor regulating CLDN2 transcription. 38, [56] [57] [58] Although investigation of the significance of the STAT-binding site in the CLDN2 promoter was the focus of this study, we also investigated whether PTPN2-KD IECs exhibited any change in expression of CDX2 and did not see any difference compared with control IECs. While we cannot at this stage rule out possible contributions of TCPTP to regulation of claudin-2 transcription by other transcription factors, particularly when challenged with appropriate cytokines, we have demonstrated a novel role for IFN-␥ stimulation of STAT-mediated claudin-2 expression in the setting of reduced TCPTP activity and expression. This has possible implications for IBD, given that subjects harboring loss-of-function mutations in PTPN2 may be further predisposed to increased claudin-2 expression and consequent alterations in intestinal barrier function. of experiments, obtained funding, and wrote and edited the manuscript.
